260 related articles for article (PubMed ID: 17449018)
41. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
[TBL] [Abstract][Full Text] [Related]
42. Accentuated vagal antagonism paradoxically increases ryanodine receptor calcium leak in long-term exercised Calsequestrin2 knockout mice.
Ho HT; Thambidorai S; Knollmann BC; Billman GE; Györke S; Kalyanasundaram A
Heart Rhythm; 2018 Mar; 15(3):430-441. PubMed ID: 29030236
[TBL] [Abstract][Full Text] [Related]
43. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations.
Kujala K; Paavola J; Lahti A; Larsson K; Pekkanen-Mattila M; Viitasalo M; Lahtinen AM; Toivonen L; Kontula K; Swan H; Laine M; Silvennoinen O; Aalto-Setälä K
PLoS One; 2012; 7(9):e44660. PubMed ID: 22962621
[TBL] [Abstract][Full Text] [Related]
44. Post-natal heart adaptation in a knock-in mouse model of calsequestrin 2-linked recessive catecholaminergic polymorphic ventricular tachycardia.
Valle G; Boncompagni S; Sacchetto R; Protasi F; Volpe P
Exp Cell Res; 2014 Feb; 321(2):178-89. PubMed ID: 24370574
[TBL] [Abstract][Full Text] [Related]
45. Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants.
Valle G; Arad M; Volpe P
J Muscle Res Cell Motil; 2020 Sep; 41(2-3):251-258. PubMed ID: 32902830
[TBL] [Abstract][Full Text] [Related]
46. Patient-Specific Human Induced Pluripotent Stem Cell Model Assessed with Electrical Pacing Validates S107 as a Potential Therapeutic Agent for Catecholaminergic Polymorphic Ventricular Tachycardia.
Sasaki K; Makiyama T; Yoshida Y; Wuriyanghai Y; Kamakura T; Nishiuchi S; Hayano M; Harita T; Yamamoto Y; Kohjitani H; Hirose S; Chen J; Kawamura M; Ohno S; Itoh H; Takeuchi A; Matsuoka S; Miura M; Sumitomo N; Horie M; Yamanaka S; Kimura T
PLoS One; 2016; 11(10):e0164795. PubMed ID: 27764147
[TBL] [Abstract][Full Text] [Related]
47. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
48. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
Katz G; Arad M; Eldar M
Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
[TBL] [Abstract][Full Text] [Related]
49. Conditional ablation and conditional rescue models for Casq2 elucidate the role of development and of cell-type specific expression of Casq2 in the CPVT2 phenotype.
Flores DJ; Duong T; Brandenberger LO; Mitra A; Shirali A; Johnson JC; Springer D; Noguchi A; Yu ZX; Ebert SN; Ludwig A; Knollmann BC; Levin MD; Pfeifer K
Hum Mol Genet; 2018 May; 27(9):1533-1544. PubMed ID: 29452352
[TBL] [Abstract][Full Text] [Related]
50. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of
Ng K; Titus EW; Lieve KV; Roston TM; Mazzanti A; Deiter FH; Denjoy I; Ingles J; Till J; Robyns T; Connors SP; Steinberg C; Abrams DJ; Pang B; Scheinman MM; Bos JM; Duffett SA; van der Werf C; Maltret A; Green MS; Rutberg J; Balaji S; Cadrin-Tourigny J; Orland KM; Knight LM; Brateng C; Wu J; Tang AS; Skanes AC; Manlucu J; Healey JS; January CT; Krahn AD; Collins KK; Maginot KR; Fischbach P; Etheridge SP; Eckhardt LL; Hamilton RM; Ackerman MJ; Noguer FRI; Semsarian C; Jura N; Leenhardt A; Gollob MH; Priori SG; Sanatani S; Wilde AAM; Deo RC; Roberts JD
Circulation; 2020 Sep; 142(10):932-947. PubMed ID: 32693635
[TBL] [Abstract][Full Text] [Related]
51. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
[TBL] [Abstract][Full Text] [Related]
52. Impaired calcium-calmodulin-dependent inactivation of Cav1.2 contributes to loss of sarcoplasmic reticulum calcium release refractoriness in mice lacking calsequestrin 2.
Kryshtal DO; Gryshchenko O; Gomez-Hurtado N; Knollmann BC
J Mol Cell Cardiol; 2015 May; 82():75-83. PubMed ID: 25758429
[TBL] [Abstract][Full Text] [Related]
53. Genetic Loss of
Reilly L; Alvarado FJ; Lang D; Abozeid S; Van Ert H; Spellman C; Warden J; Makielski JC; Glukhov AV; Eckhardt LL
Circ Arrhythm Electrophysiol; 2020 Sep; 13(9):e008638. PubMed ID: 32931337
[TBL] [Abstract][Full Text] [Related]
54. Interplay between Triadin and Calsequestrin in the Pathogenesis of CPVT in the Mouse.
Cacheux M; Fauconnier J; Thireau J; Osseni A; Brocard J; Roux-Buisson N; Brocard J; Fauré J; Lacampagne A; Marty I
Mol Ther; 2020 Jan; 28(1):171-179. PubMed ID: 31607542
[TBL] [Abstract][Full Text] [Related]
55. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age.
Denegri M; Bongianino R; Lodola F; Boncompagni S; De Giusti VC; Avelino-Cruz JE; Liu N; Persampieri S; Curcio A; Esposito F; Pietrangelo L; Marty I; Villani L; Moyaho A; Baiardi P; Auricchio A; Protasi F; Napolitano C; Priori SG
Circulation; 2014 Jun; 129(25):2673-81. PubMed ID: 24888331
[TBL] [Abstract][Full Text] [Related]
56. Functional Calsequestrin-1 Is Expressed in the Heart and Its Deficiency Is Causally Related to Malignant Hyperthermia-Like Arrhythmia.
Sun Z; Wang L; Han L; Wang Y; Zhou Y; Li Q; Wu Y; Talabieke S; Hou Y; Wu L; Liu R; Fu Z; You H; Li BY; Zheng Y; Luo D
Circulation; 2021 Sep; 144(10):788-804. PubMed ID: 34162222
[TBL] [Abstract][Full Text] [Related]
57. Alternating membrane potential/calcium interplay underlies repetitive focal activity in a genetic model of calcium-dependent atrial arrhythmias.
Lou Q; Belevych AE; Radwański PB; Liu B; Kalyanasundaram A; Knollmann BC; Fedorov VV; Györke S
J Physiol; 2015 Mar; 593(6):1443-58. PubMed ID: 25384790
[TBL] [Abstract][Full Text] [Related]
58. Characterization of the first induced pluripotent stem cell line generated from a patient with autosomal dominant catecholaminergic polymorphic ventricular tachycardia due to a heterozygous mutation in cardiac calsequestrin-2.
Ross S; Holliday M; Lim S; Semsarian C
Stem Cell Res; 2019 May; 37():101450. PubMed ID: 31039485
[TBL] [Abstract][Full Text] [Related]
59. Decreased RyR2 refractoriness determines myocardial synchronization of aberrant Ca2+ release in a genetic model of arrhythmia.
Brunello L; Slabaugh JL; Radwanski PB; Ho HT; Belevych AE; Lou Q; Chen H; Napolitano C; Lodola F; Priori SG; Fedorov VV; Volpe P; Fill M; Janssen PM; Györke S
Proc Natl Acad Sci U S A; 2013 Jun; 110(25):10312-7. PubMed ID: 23733959
[TBL] [Abstract][Full Text] [Related]
60. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
